ovarian cancer
Showing NaN - NaN of 86
Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Worldwide (biological, drug, other)
Recruiting
- Ovarian Cancer
- +2 more
- Pembrolizumab
- +4 more
-
Phoenix, Arizona
- +178 more
Jan 25, 2023
NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)
Recruiting
- Non-small Cell Lung Cancer
- +11 more
-
Birmingham, Alabama
- +32 more
Jan 4, 2023
Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))
Completed
- Ovarian Cancer
- +7 more
- Enapotamab vedotin (HuMax-AXL-ADC)
-
Phoenix, Arizona
- +40 more
Dec 12, 2022
Ovarian Cancer Trial in Worldwide (VS-6766, VS-6766 and Defactinib)
Recruiting
- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer
- avutometinib (VS-6766)
- avutometinib (VS-6766) and Defactinib
-
Scottsdale, Arizona
- +46 more
Dec 29, 2022
NSCLC, Pancreatic Cancer, Colorectal Cancer Trial in Canada, United States (PF-06946860, Placebo for PF-06946860)
Completed
- Non-small Cell Lung Cancer
- +9 more
- PF-06946860
- Placebo for PF-06946860
-
Little Rock, Arkansas
- +32 more
Dec 12, 2022
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High Trial in United States
Recruiting
- Advanced or Metastatic Solid Tumors
- +11 more
-
Tucson, Arizona
- +11 more
Dec 2, 2022
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma Trial in France, United States (TRK-950, Irinotecan, Leucovorin)
Recruiting
- Solid Tumor
- +11 more
- TRK-950
- +14 more
-
Scottsdale, Arizona
- +13 more
Oct 2, 2022
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Tumors Trial in Worldwide (Pembrolizumab, Placebo for pembrolizumab,
Active, not recruiting
- Ovarian Cancer
- +2 more
- Pembrolizumab
- +7 more
-
Birmingham, Alabama
- +226 more
Aug 22, 2022
Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer Trial in Worldwide (Pembrolizumab, Lenvatinib)
Active, not recruiting
- Advanced Solid Tumors
- +7 more
- Pembrolizumab
- Lenvatinib
-
Duarte, California
- +87 more
Aug 19, 2022
Advanced Cancer, Ovarian Cancer, Lung Cancer Trial in United States (Dose escalation: COM902 monotherapy., Evaluation of
Recruiting
- Advanced Cancer
- +6 more
- Dose escalation: COM902 monotherapy.
- +3 more
-
Grand Rapids, Michigan
- +5 more
Aug 8, 2022
NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- CPI-006
- +2 more
-
Tucson, Arizona
- +26 more
Aug 1, 2022
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
-
Anchorage, Alaska
- +55 more
Jul 25, 2022
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,
Recruiting
- Any Advanced Solid Tumors
- +6 more
-
Tampa, Florida
- +7 more
Jul 13, 2022
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Worldwide (tisotumab vedotin)
Completed
- Ovarian Cancer
- +2 more
- tisotumab vedotin
-
San Jose, California
- +36 more
Jul 8, 2022
Ovarian Cancer Trial in Worldwide (NovoTTF-100L(O), Paclitaxel)
Active, not recruiting
- Ovarian Cancer
- NovoTTF-100L(O)
- Paclitaxel
-
Phoenix, Arizona
- +118 more
Apr 19, 2022
Acute Myeloid Leukemia, MDS, Glioblastoma Multiforme Trial in United States (DSP-7888 Dosing Emulsion)
Completed
- Acute Myeloid Leukemia
- +8 more
- DSP-7888 Dosing Emulsion
-
Denver, Colorado
- +7 more
Apr 4, 2022
Ovarian Cancer, Breast Cancer Trial in Dallas (Lynparza)
Active, not recruiting
- Ovarian Cancer
- Breast Cancer
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
Mar 22, 2022
Ovarian Cancer, Hepatocellular Carcinoma, NSCLC Trial in Canada, United States (DPX-Survivac, Cyclophosphamide, Pembrolizumab)
Active, not recruiting
- Ovarian Cancer
- +4 more
- DPX-Survivac
- +2 more
-
Tucson, Arizona
- +22 more
Mar 28, 2022